Palavras-chave
Saccharomyces boulardii
Nefropatias
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Avaliar a atividade renal de camundongos infectados com Schistosoma mansoni Cepa BH e tratados com Saccharomyces boulardii CNCM I-745, por meio da quantificação de marcadores bioquímicos, visando investigar possíveis efeitos protetores do probiótico sobre a função renal durante a esquistossomose. Métodos: Camundongos fêmeas Swiss Webster (n=70) foram infectados com Schistosoma mansoni Cepa BH e sete grupos experimentais foram formados, incluindo controles negativos e positivos, grupos tratados com Saccharomyces boulardii por diferentes períodos e um grupo tratado com Praziquantel. Após as intervenções, foram mensurados os níveis séricos de ácido úrico, lactato, ureia, creatinina e albumina como indicadores da função renal. Resultados: Os grupos tratados com Saccharomyces boulardii apresentaram redução significativa dos níveis de ácido úrico, creatinina e lactato em comparação ao grupo controle positivo. Também foi observada melhora nos níveis de ureia e albumina, principalmente nos grupos cuja intervenção foi mais prolongada, bem como no grupo tratado com Praziquantel. Conclusão: A administração de Saccharomyces boulardii CNCM I-745 reduziu alterações bioquímicas associadas à disfunção renal induzida por Schistosoma mansoni Cepa BH, indicando um potencial efeito nefroprotetor como adjuvante no tratamento da esquistossomose.
Referências
ABREU ICME, et al. Saccharomyces boulardii exerts renoprotection by modulating oxidative stress, renin angiotensin system and uropathogenic microbiota in a murine model of diabetes. Life Sciences, 2022; 301: 120616.
AFRIFA J, et al. Oxidative stress and cancer risk in schistosomiasis. Oxidative Medicine and Cellular Longevity, 2024; 2024: 9701021.
ALMEIDA AFG. Glomerulopatia esquistossomótica: comportamento das alterações em camundongos infectados pelo Schistosoma mansoni, antes e depois do tratamento com praziquantel. Dissertação de Mestrado, Salvador, 2013.
BARSOUM R. Schistosomal glomerulopathies. Kidney International, 1993; 1-12.
BOTONI FA, et al. Functional autoantibodies against G protein-coupled receptors in hepatic and pulmonary hypertensions in human schistosomiasis. Frontiers in Immunology, 2024; 15: 1404384.
BRASIL. MINISTÉRIO DA SAÚDE. Vigilância em saúde no Brasil 2003|2019: da criação da Secretaria de Vigilância em Saúde aos dias atuais. Boletim Epidemiológico, 2019.
BUONFRATE D, et al. Human schistosomiasis. The Lancet, 2025; 405: 658–670.
CHEN H, et al. Bacillus amyloliquefaciens alleviates the pathological injuries in mice infected with Schistosoma japonicum by modulating intestinal microbiome. Frontiers in Cellular and Infection Microbiology, 2023; 13: 1172298.
CHEN H, et al. Multi-omics analyses of Bacillus amyloliquefaciens treated mice infected with Schistosoma japonicum reveal dynamics change of intestinal microbiome and its associations with host metabolism. PLoS Neglected Tropical Diseases, 2024; 18(10): 12583.
CHENG T, et al. The level of serum albumin is associated with renal prognosis and renal function decline in patients with chronic kidney disease. BMC Nephrology, 2023; 24: 57.
COLLEY DG, et al. Human schistosomiasis. Lancet, 2014; 383(9936): 2253–2264.
CRUZ CS, et al. In vitro and in vivo evaluation of Bacillus clausii against Schistosoma mansoni. Acta Tropica, 2022; 235: 106669.
CUI X, et al. Uric acid reduces the expression of aquaporins in renal collecting ducts to increase urine output in hyperuricemia. Frontiers in Physiology, 2025; 16: 1504328.
EGEA MB, et al. Investigating the efficacy of Saccharomyces boulardii in metabolic syndrome treatment: a narrative review of what is known so far. Int J Mol Sci, 2023; 24(15): 12015.
EL-KHADRAGY MF, et al. Probiotics and yogurt modulate oxidative stress and fibrosis in livers of Schistosoma mansoni-infected mice. BMC Complementary and Alternative Medicine, 2019; 19: 3.
FERNANDES JPM, et al. Esquistossomose no Brasil: Uma análise epidemiológica sobre as repercussões clínicas no aparelho digestivo e nos parâmetros de Saúde Pública. Brazilian Journal of Implantology and Health Sciences, 2024; 6(11): 240-267.
GALVÃO RLF, et al. Kidney injury biomarkers and parasitic loads of Schistosoma mansoni in a highly endemic area in northeastern Brazil. Acta Tropica, 2022; 228: 106311.
GLIDDEN C, et al. Climate and urbanization drive changes in the habitat suitability of Schistosoma mansoni competent snails in Brazil. Nature Communications, 2024; 15: 4838.
KDIGO. KDIGO CKD WORK GROUP. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024; 105(4): 117-314.
KIM SG, et al. Hyperlactatemia is a predictor of mortality in patients undergoing continuous renal replacement therapy for acute kidney injury. BMC Nephrology, 2023; 24: 11.
KOKALIARIS C, et al. Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study. Lancet Infectious Diseases, 2022; 136-149.
LIN D, et al. Bacillus subtilis attenuates hepatic and intestinal injuries and modulates gut microbiota and gene expression profiles in mice infected with Schistosoma japonicum. Frontiers in Cell and Developmental Biology, 2021; 9: 766205.
LOPES-JUNIOR EH, et al. Human tumor necrosis factor alpha affects the egg-laying dynamics and glucose metabolism of Schistosoma mansoni adult worms in vitro. Parasites & Vectors, 2022; 15(1): 176.
MASLENNIKOV R, et al. Effect of Saccharomyces boulardii on liver diseases: a systematic review. Microorganisms, 2024; 12(8): 1678.
MCFARLAND L. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World Journal of Gastroenterology, 2010; 2202-2222.
NEVES PDM, et al. Schistosomiasis-associated glomerulopathy: Clinical aspects, pathological characteristics, and renal outcomes. Clinical Nephrology, 2020; 93(5): 251–261.
PAIS P, et al. Saccharomyces boulardii: What Makes It Tick as Successful Probiotic? Journal of Fungi, 2020; 6: 1-16.
PERDICHIZZI A, et al. Growth and Immune Response Parameters. Animals, 2023; 13(21): 3383.
REILY C, et al. Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy. American Journal of Physiology-Renal Physiology, 2024.
REINHOLDT C, et al. Unisexual infection with Schistosoma mansoni in mice has the potential to restore immune balance and induce liver fibrosis. Front Immunol. 2023; 14: 1125912.
SANTOS VHB, et al. Effects of the probiotic Bacillus cereus GM on experimental schistosomiasis mansoni. Parasitology Research, 2024; 123: 72.
SIDIBÉ B, et al. Human-water interactions associated to cercarial emergence pattern and their influences on urinary schistosomiasis transmission in two endemic areas in Mali. Infectious Diseases of Poverty, 2024; 13(1): 62.
SOUSA MS, et al. Subclinical signs of podocyte injury associated with Circulating Anodic Antigen (CAA) in Schistosoma mansoni-infected patients in Brazil. Revista da Sociedade Brasileira de Medicina Tropical, 2023; 56: 341.
WILLIAMS M, et al. Kidney Pathology of Tropical and Nontropical Infectious Diseases in the Pediatric Population. American Journal of Clinical Pathology, 2023; 159(2): 129-137.
XIAO SH, et al. Pharmacological and immunological effects of praziquantel against Schistosoma japonicum: a scoping review of experimental studies. Infectious Diseases of Poverty, 2018; 7: 9.
YU X, et al. Alleviating effects of probiotic supplementation on biomarkers of inflammation and oxidative stress in non-communicable diseases: a systematic review and meta-analysis using the GRADE approach. BMC Pharmacology and Toxicology, 2025; 26: 124.